Predict your next investment

HEALTHCARE | Drug Development
daniolabs.com

See what CB Insights has to offer

Founded Year

2002

Stage

Acquired | Acquired

Total Raised

$12.24M

About Danio Labs

Developer of therapeutics for neurological, ophthalmological, and metabolic diseases. The company's two main objectives are investigating new uses for established drugs (reprofiling), and providing phenotypic evaluation of compounds for other organisations, either for activity effects, or for preclinical safety pharmacology. As part of the company's approach, zebrafish are used as a key enabling technology. Their size allows them to be used to evaluate the effects of compounds in human disease models.

Danio Labs Headquarter Location

7330 Cambridge Research Park

Cambridge, CB5 9TN,

United Kingdom

44 122 370 6460

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.